NUMERO: #20230708

Título: CREB INHIBITOR THERAPY FOR MUCOEPIDERMOID CARCINOMA

Nome do Apresentador: Maria Eduarda PÉREZ-DE-OLIVEIRA

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Patologia Oral

Resumo: Objectives: Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor and about 50% of cases have the CRTC1-MAML2 translocation. The CREB pathway has been associated with the transforming activity of CRTC1-MAML2. The aim of this study was to determine the effects of CREB inhibition on MECs cells behavior in vitro. Study design: Three MEC cell lines (UM-HMC-2, H292, H253) were treated with the CREB-inhibitor, 666.15. Drug IC50 doses were determined for each cell line and CREB-inhibition was confirmed through mRNA levels of downstream target NURR1. Clonogenic and sphere assays were used to assess survival and percentage of cancer stem cells (CSC) and transwell and scratch assays to evaluate the cells invasive and migratory capacity. Results: CREB-inhibition was confirmed by reduced transcript levels of NURR1. The drug significantly delayed cell invasion. The number of surviving colonies was also significantly reduced following drug exposure. Conclusion: CREB inhibition efficiently impaired MEC key oncogenic behavior associated with metastasis and drug resistance, such as cell invasion and survival respectively. This study was supported by FAPESP (2019/26676-6 and 2021/10810-6).

Autor 1:  Maria Eduarda PÉREZ-DE-OLIVEIRA

E-mail 1:  [email protected]

Autor 2:   Vivian Petersen WAGNER

E-mail 2:  [email protected]

Autor 3 :  Colin D. BINGLE

E-mail 3:  [email protected]

Autor 4:  Pablo Agustin VARGAS

E-mail 4:  [email protected]

Autor 5:  Lynne BINGLE

E-mail 5:  [email protected]